Overview
Tiba Biotech is a preclinical stage biopharmaceutical company developing next-generation RNA vaccines and therapeutics based on a novel dendrimer nanoparticle delivery platform initially developed at the Massachusetts Institute of Technology and the Whitehead Institute for Biomedical Research. Tiba Biotech’s nanoparticle delivery platform can safely enable large vaccine and therapeutic payloads, with relaxed cold-chain requirements and superior safety compared to existing RNA technologies, to provide protection against multiple human and animal diseases. For more information about Tiba Biotech, visit www.tiba.bio
Company News
